{
    "biomarker_id": "AN6681-1",
    "biomarker_canonical_id": "AN6681",
    "condition": {
        "recommended_name": {
            "id": "DOID:363",
            "resource": "Disease Ontology",
            "url": "https://disease-ontology.org/term/DOID:363",
            "name": "uterine cancer",
            "description": "A female reproductive organ cancer that is located_in the uterus."
        },
        "synonyms": [
            {
                "id": "DOID:363",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:363",
                "name": "CA - cancer of uterus",
                "description": ""
            },
            {
                "id": "DOID:363",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:363",
                "name": "Tumour of uterus",
                "description": ""
            },
            {
                "id": "DOID:363",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:363",
                "name": "malignant neoplasm of uterus",
                "description": ""
            },
            {
                "id": "DOID:363",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:363",
                "name": "malignant uterine tumor",
                "description": ""
            },
            {
                "id": "DOID:363",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:363",
                "name": "neoplasm of uterus",
                "description": ""
            },
            {
                "id": "DOID:363",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:363",
                "name": "uterine tumor",
                "description": ""
            },
            {
                "id": "DOID:363",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:363",
                "name": "uterus neoplasm",
                "description": ""
            }
        ],
        "id": "DOID:363"
    },
    "biomarker_component": [
        {
            "biomarker": "increased IMP3 level",
            "assessed_biomarker_entity_id": "Q9NV31-1",
            "assessed_entity_type": "protein",
            "assessed_biomarker_entity": {
                "recommended_name": "U3 small nucleolar ribonucleoprotein protein IMP3",
                "synonyms": [
                    {
                        "synonym": "BRMS2"
                    }
                ]
            },
            "specimen": [
                {
                    "name": "uterus",
                    "namespace": "UBERON",
                    "id": "0000995",
                    "url": "http://purl.obolibrary.org/obo/UBERON_0000995",
                    "loinc_code": ""
                }
            ],
            "evidence_source": [
                {
                    "id": "AN6681-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6681-1"
                },
                {
                    "id": "18223334",
                    "database": "PubMed",
                    "url": "https://glygen.org/publication/PubMed/18223334",
                    "tags": [
                        "assessed_biomarker_entity",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "IMP3 expression was predominantly found in endometrial serous carcinoma and its putative precursor lesions, with 3 (14%) of 21 endometrial glandular dysplasia, 16 (89%) of 18 serous endometrial intraepithelial carcinoma, and 48 (94%) of 51 serous carcinomas (P<0.001). We conclude that expression of IMP3, a newly identified cytoplasmic marker, is closely associated with type II endometrial cancer. It seems that IMP3 expression is associated with an aggressive histologic phenotype among endometrial neoplastic lesions. Strong and diffuse IMP3 expression is highly sensitive for endometrial serous and clear cell carcinomas including their putative precursor lesions. Therefore, IMP3 may be a useful diagnostic marker in the assessment of endometrial cancers and their precursor lesions, particularly when the amount of available tissue material is limited and a concern of type II cancer arises."
                        }
                    ]
                }
            ]
        }
    ],
    "best_biomarker_role": [
        {
            "role": "prognostic"
        }
    ],
    "evidence_source": [
        {
            "id": "AN6681-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/AN6681-1"
        },
        {
            "id": "18223334",
            "database": "PubMed",
            "url": "https://glygen.org/publication/PubMed/18223334",
            "tags": [
                "best_biomarker_role",
                " condition"
            ],
            "evidence_list": [
                {
                    "evidence": "IMP3 expression was predominantly found in endometrial serous carcinoma and its putative precursor lesions, with 3 (14%) of 21 endometrial glandular dysplasia, 16 (89%) of 18 serous endometrial intraepithelial carcinoma, and 48 (94%) of 51 serous carcinomas (P<0.001). We conclude that expression of IMP3, a newly identified cytoplasmic marker, is closely associated with type II endometrial cancer. It seems that IMP3 expression is associated with an aggressive histologic phenotype among endometrial neoplastic lesions. Strong and diffuse IMP3 expression is highly sensitive for endometrial serous and clear cell carcinomas including their putative precursor lesions. Therefore, IMP3 may be a useful diagnostic marker in the assessment of endometrial cancers and their precursor lesions, particularly when the amount of available tissue material is limited and a concern of type II cancer arises."
                }
            ]
        }
    ],
    "crossref": [
        {
            "id": "AN6681-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/AN6681-1",
            "categories": [
                "Biomarkers"
            ]
        }
    ],
    "citation": [
        {
            "title": "The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.",
            "journal": "The American journal of surgical pathology",
            "authors": "Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z",
            "date": "2008",
            "reference": [
                {
                    "type": "PubMed",
                    "id": "18223334",
                    "url": "https://glygen.org/publication/PubMed/18223334"
                }
            ],
            "evidence": [
                {
                    "id": "AN6680-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6681-1"
                }
            ]
        }
    ],
    "section_stats": [
        {
            "table_id": "biomarker_component",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "biomarker",
                "assessed_biomarker_entity_id",
                "assessed_entity_type",
                "assessed_biomarker_entity.recommended_name"
            ]
        },
        {
            "table_id": "citation",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "title",
                "journal",
                "authors",
                "date"
            ]
        }
    ]
}